{"contentid": 488378, "importid": NaN, "name": "FDA revokes EUA for MAb bamlanivimab for COVID-19", "introduction": "The US Food and Drug Administration on Friday revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.", "content": "<p>The US Food and Drug Administration on Friday <a href=\"https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTA0MTYuMzg5NDk3NjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE0NzYyOS9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.YnjWVlVVKWriWiPR4ngTD59bjvPdc5yzTXUIuJdZbco/s/1255922260/br/102596253589-l\">revoked the emergency use authorization</a> (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.</p>\n<p>Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment failure, the FDA has determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use.</p>\n<p>Therefore, the agency determined that the criteria for issuance of an authorization are no longer met and has revoked the EUA. The drug continues to be authorized for use together with etesevimab under EUA 094.</p>\n<h2><strong>EUA issued in November 2020</strong></h2>\n<p>On November 9, 2020, based on the totality of scientific evidence available at the time, the FDA issued an EUA to US pharma major Eli Lilly (NYSE: LLY) authorizing the emergency use of bamlanivimab alone for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.</p>\n<p>Last October, ahead of the EUA granting, Eli Lilly announced an initial agreement with the US government to supply 300,000 vials of bamlanivimab 700mg for $375 million.</p>\n<p>Importantly, although the FDA is now revoking this EUA, alternative monoclonal antibody therapies remain available under EUA, including <a href=\"https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTA0MTYuMzg5NDk3NjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE0NTYxMC9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.eMd9htWKShopueHfLAFP0dc9MAtL3jNSK75MuF5Dpqc/s/1255922260/br/102596253589-l\">REGEN-COV (casirivimab and imdevimab, administered together)</a>, and <a href=\"https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDMsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTA0MTYuMzg5NDk3NjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE0NTgwMS9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.q2lpUWmw1rREtINRPkksOf93JxeTH0Xx5GR4CI_k7Tw/s/1255922260/br/102596253589-l\">bamlanivimab and etesevimab, administered together</a>, for the same uses as previously authorized for bamlanivimab alone. The FDA believes that these alternative monoclonal antibody therapies remain appropriate to treat patients with COVID-19 when used in accordance with the authorized labeling based on information available at this time.</p>", "date": "2021-04-17 13:21:00", "meta_title": "FDA revokes EUA for MAb bamlanivimab for COVID-19", "meta_keywords": "Eli Lilly, Bamlanivimab, Emergency use, Authorization, Revoked, EUA, FDA, COVID-19", "meta_description": "FDA revokes EUA for MAb bamlanivimab for COVID-19", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-17 13:21:18", "updated": "2021-04-17 13:29:00", "access": NaN, "url": "https://www.thepharmaletter.com/article/fda-revokes-eua-for-mab-bamlanivimab-for-covid-19", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "coronavirus_structure_large.jpg", "image2id": "coronavirus_structure_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases", "topic_tag": "Coronavirus, Focus On, Regulation, US FDA", "geography_tag": "USA", "company_tag": "Eli Lilly", "drug_tag": "bamlanivimab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-17 13:21:00"}